Gossamer Bio Faces Class Action Lawsuit Amid Securities Fraud Allegations

On May 22, 2026, Robbins LLP announced critical news for investors in Gossamer Bio, Inc. (NASDAQ: GOSS). A class action lawsuit has been filed on behalf of shareholders who purchased the company's securities during the period from June 16, 2025, to February 20, 2026. This development raises significant concerns regarding allegations of securities fraud, which may have affected the stock's value tremendously.

Gossamer Bio is a clinical-stage biopharmaceutical firm focused on developing seralutinib, a drug aimed at treating pulmonary hypertension associated with interstitial lung disease. Unfortunately, this promising venture has recently come under scrutiny.

The Allegations Behind the Lawsuit

The class action relates to misleading statements made by Gossamer Bio concerning the effectiveness and prospects of its PROSERA study. The complaint indicates that the company's executives conveyed overly optimistic information to investors while concealing material adverse facts about the Phase 3 trial's design, particularly regarding the placebo response noted in Latin America testing sites. This lack of transparency led to shareholders purchasing Gossamer's securities at artificially inflated prices.

The primary allegations suggest that the company was aware of the significant issues surrounding the trial's design but opted not to disclose this information. According to the complaint, these misleading communications included affirmations about the validity of the trial design and the resulting confidence in its outcomes.

The Impact of the Trial Results

The situation escalated when Gossamer Bio published its press release on February 23, 2026, revealing that the PROSERA trial failed to meet its primary endpoint—the six-minute walk distance (6MWD) improvement required at Week 24. Subsequently, the trial demonstrated a mere +13.3 meter placebo-adjusted gain, which did not meet the necessary 0.025 alpha threshold. The company justified this failure by citing an unusually high performance on placebo by patients enrolled at the Latin American sites, which were part of a heavily treated lower-risk population.

This disheartening news had a devastating effect on Gossamer's stock value, which plummeted from $2.13 per share on February 20, 2026, to $0.42 within days, resulting in an astounding loss of over 80% in just a single day's trading.

What It Means for Shareholders

For investors who feel affected by this recent turn of events, there may still be avenues for redress. Shareholders may be eligible to participate in the class action lawsuit against Gossamer Bio. Those interested in taking a more active role can submit their paperwork to become a lead plaintiff by June 1, 2026. A lead plaintiff serves as a representative for other class members and guides the litigation.

Importantly, participation in the lawsuit is not a prerequisite for recovery; entities who opt to refrain from action can maintain their status as absent class members. Robbins LLP has committed to representing shareholders on a contingency fee basis, meaning no fees are owed unless a recovery is achieved.

About Robbins LLP

Established in 2002, Robbins LLP is a reputable firm dedicated to defending shareholders' rights. Their dedicated team has focused on enhancing corporate governance and holding company leaders accountable for misconduct that affects investor interests.

For investors wanting to stay updated on this lawsuit or for further information about potential involvement, it is recommended to contact Robbins LLP directly, either through their website or via phone at (800) 350-6003.

In the dynamic world of biopharmaceuticals, remaining informed and proactive has never been more critical. The case of Gossamer Bio underscores the importance of transparency and accountability in corporate communications. As developments unfold, additional updates are expected as shareholders navigate this complex legal landscape.